Sandoz has acquired worldwide rights to Korean player Alteogen’s novel human recombinant human hyaluronidase enzyme (ALT-B4) to develop and commercialize a subcutaneous version of one of its own biosimilar products.
Meanwhile, the Novartis affiliate’s agreement includes an option for Sandoz to license ALT-B4, which is derived using the company’s Hybrozyme...






